(INNS)
SACITUZUMAB(SLE)
SACITUZUMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS TACSTD2 (TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2, MEMBRANE COMPONENT CHROMOSOME 1 SURFACE MARKER 1, M1S1, GASTROINTESTINAL TUMOR-ASSOCIATED ANTIGEN GA7331, PANCREATIC CARCINOMA MARKER PROTEIN GA733-1, EPITHELIAL GLYCOPROTEIN-1, EGP-1, TROPHOBLAST ANTIGEN-2, CELL SURFACE GLYCOPROTEIN TROP-2, TROP2)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-451) [HUMANIZED VH (HOMO SAPIENS IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -HOMO SAPIENS IGHG1*03, G1M3 (CH1 (122-219), HINGE (220-234), CH2 (235-344), CH3 (345- 449), CHS (450-451)) (122-451)], (224-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') - HOMO SAPIENS IGKC*01, KM3 (108'-214')]; DIMER (230- 230":233-233")-BISDISULFIDE, RECOMMENDED INN: LIST 77(WHO)
SACITUZUMABUM(INN)